Jericho Sciences is developing novel antiviral therapeutics and corresponding personalized diagnostic assays which specifically address the limitations of current therapies in the clinical management of chronic viral infections.
The target motif of our small molecule therapeutic approach is shared across multiple virus families, including those of potential pandemic threat.
